a-182086

**A-182086** is a small molecule drug developed as a dual endothelin receptor antagonist, targeting both endothelin receptor type A (ETA) and type B (ETB). It inhibits the action of endothelin-1 at these receptors, with the goal of modulating vascular tone and reducing pathological vasoconstriction and fibrosis. Preclinical and translational studies have investigated its use in cardiovascular diseases such as heart failure, hypertension, and kidney disease, including diabetic nephropathy and sickle cell nephropathy. A-182086 has shown efficacy in reducing proteinuria and glomerular permeability, but in certain disease models, selective ETA antagonists may provide superior anti-inflammatory and antifibrotic effects. Development has not progressed past early-phase evaluation, and clinical approval is not reported[1][3].